Declan C Murphy1,2,3, Mohamed Katta1, Catherine A Egan1,4, Michel Michaelides1,4, Louisa Wickham5. 1. Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK. 2. Institute of Genetic Medicine, Newcastle University, Tyne and Wear, UK. 3. Northumbria Healthcare NHS Foundation Trust, Tyne and Wear, UK. 4. UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK. 5. Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK. louisa.wickham1@nhs.net.
Abstract
PURPOSE: Albinism defines a group of genetic diseases which result from disordered melanin biosynthesis. Proliferative diabetic retinopathy (PDR) results from poorly controlled type 1 or 2 diabetes mellitus (DM) and can lead to blindness due to progressive neovascularisation. However, the treatment of PDR in patients with ocular/oculocutaneous albinism may be more challenging. In this study, we compared a group of patients with albinism and PDR, to a group with albinism and diabetes mellitus but no PDR, to examine the long-term implications. METHODS: Retrospective observational study included all patients with ocular albinism (OA) or oculocutaneous albinism (OCA) and DM who presented at a single specialist centre. Participants were allocated into either group 1 (eyes with PDR) or group 2 (all eyes without PDR). Statistical analysis was performed using SPSS V26.0. Between-group differences were investigated. RESULTS: Outcome data was available for 5 eyes from 3 participants in group 1 and 26 eyes from 13 participants in group 2. Despite interventions, a large and significant difference in vision at follow-up was observed between group 1 and group 2 (mean change in visual acuity: 1.11 (± 1.00) versus - 0.15 (± 0.46), respectively; p = < 0.0001). CONCLUSION: PDR is associated with poor long-term prognosis despite interventions for patients with albinism. Those without PDR appear to maintain stable vision. Alternative treatments for PDR and its complications may be required in this population. Measures to prevent the development of diabetic eye disease and progression towards PDR should be employed at an early stage.
PURPOSE: Albinism defines a group of genetic diseases which result from disordered melanin biosynthesis. Proliferative diabetic retinopathy (PDR) results from poorly controlled type 1 or 2 diabetes mellitus (DM) and can lead to blindness due to progressive neovascularisation. However, the treatment of PDR in patients with ocular/oculocutaneous albinism may be more challenging. In this study, we compared a group of patients with albinism and PDR, to a group with albinism and diabetes mellitus but no PDR, to examine the long-term implications. METHODS: Retrospective observational study included all patients with ocular albinism (OA) or oculocutaneous albinism (OCA) and DM who presented at a single specialist centre. Participants were allocated into either group 1 (eyes with PDR) or group 2 (all eyes without PDR). Statistical analysis was performed using SPSS V26.0. Between-group differences were investigated. RESULTS: Outcome data was available for 5 eyes from 3 participants in group 1 and 26 eyes from 13 participants in group 2. Despite interventions, a large and significant difference in vision at follow-up was observed between group 1 and group 2 (mean change in visual acuity: 1.11 (± 1.00) versus - 0.15 (± 0.46), respectively; p = < 0.0001). CONCLUSION: PDR is associated with poor long-term prognosis despite interventions for patients with albinism. Those without PDR appear to maintain stable vision. Alternative treatments for PDR and its complications may be required in this population. Measures to prevent the development of diabetic eye disease and progression towards PDR should be employed at an early stage.
Authors: Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck Journal: JAMA Date: 2015-11-24 Impact factor: 56.272
Authors: Mahiul M K Muqit; Chintan Sanghvi; Rita McLauchlan; Christine Delgado; Lorna B Young; Stephen J Charles; George R Marcellino; Paulo E Stanga Journal: Acta Ophthalmol Date: 2010-02-16 Impact factor: 3.761
Authors: C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: S Harding; R Greenwood; S Aldington; J Gibson; D Owens; R Taylor; E Kohner; P Scanlon; G Leese Journal: Diabet Med Date: 2003-12 Impact factor: 4.359
Authors: Ahmad M Mansour; Jay Chhablani; J Fernando Arevalo; Lihteh Wu; Ravi Sharma; Suthasinee Sinawat; Tharikarn Sujirakul; Alexandre Assi; Wandsy M Vélez-Vázquez; Mohamad A Mansour; Ozcan Kayikcioglu; Cem Kucukerdonmez; Ali Kal Journal: Clin Ophthalmol Date: 2018-04-05